Literature DB >> 18974488

Study of metallo-beta-lactamase production in clinical isolates of Pseudomonas aeruginosa.

G Agrawal1, R B Lodhi, U P Kamalakar, R K Khadse, S V Jalgaonkar.   

Abstract

A study of metallo-beta-lactamase (MBL) production was done in clinical isolates of Pseudomonas aeruginosa. Isolates resistant to ceftazidime and imipenem were screened for MBL production by double disc synergy test (DDST) and minimum inhibitory concentration reduction test. There was complete correlation between two methods for imipenem. For ceftazidime, there was correlation between the two methods in all except four strains. In the screening test for MBL, ceftazidime-EDTA combination was better than imipenem-EDTA combination. 8.05% strains were MBL producers. Presence of MBL producer P. aeruginosa is a cause of concern. Simple DDST can be helpful for monitoring of these emerging resistant determinants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974488     DOI: 10.4103/0255-0857.43573

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  2 in total

1.  Growing Menace of Antibacterial Resistance in Clinical Isolates of Pseudomonas aeruginosa in Nepal: An Insight of Beta-Lactamase Production.

Authors:  Shamshul Ansari; Rabindra Dhital; Sony Shrestha; Sangita Thapa; Ram Puri; Niraj Chaudhary; Suresh Khatiwada; Rajendra Gautam
Journal:  Biomed Res Int       Date:  2016-08-23       Impact factor: 3.411

2.  Detection of extended spectrum beta lactamases, ampc beta lactamases and metallobetalactamases in clinical isolates of ceftazidime resistant Pseudomonas Aeruginosa.

Authors:  Sivaraman Umadevi; Noyal M Joseph; Kandha Kumari; Joshy M Easow; Shailesh Kumar; Selvaraj Stephen; Sreenivasan Srirangaraj; Sruthi Raj
Journal:  Braz J Microbiol       Date:  2011-12-01       Impact factor: 2.476

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.